N※N

Sigyn Therapeutics to Present at the Life Sciences Virtual Investor Forum on September 18th

  //science-technology.news-articles.net/content/2 .. es-virtual-investor-forum-on-september-18th.html
  Published in Science and Technology on Tuesday, September 16th 2025 at 15:29 GMT by Toronto Star
          ^{🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source}

Sigyn Therapeutics Announces Virtual Investor Forum on September 18: A Deep Dive into the Company’s Pipeline, Progress and Future Plans

On September 18 2023, clinical‑stage biopharmaceutical company Sig yn Therapeutics will host a live, virtual investor forum in partnership with Life Sciences Virtual Investor Forum. The event, slated for 2:00 p.m. ET, will give institutional and retail investors a chance to hear directly from the company’s senior leadership, explore its latest data, and ask questions in a live Q&A session. The forum is part of Sig yn’s ongoing effort to keep shareholders informed about its clinical‑development trajectory, commercial strategy, and financial position.

Company Snapshot

Sig yn Therapeutics (NASDAQ: SGY) focuses on discovering, developing and commercializing small‑molecule immunotherapies that target the immune system’s regulatory checkpoints. The company’s proprietary platform centers on modulating the T‑cell immunoglobulin and mucin‑domain‑containing protein 3 (TIM‑3) pathway—a key driver of T‑cell exhaustion in cancer and chronic infection. By combining a potent TIM‑3 inhibitor with a complementary checkpoint inhibitor, Sig yn aims to reinvigorate anti‑tumor T‑cell responses while minimizing toxicity.

In addition to oncology, Sig yn’s pipeline includes candidates for autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company’s portfolio is organized into three phases:

The latest data presented at the forum will focus on the interim safety and pharmacokinetic profile of SGT‑120, which has already shown a favorable safety window in a 28‑day open‑label cohort of 20 patients.

Financial Highlights and Recent Funding

Sig yn’s latest quarterly report, released in the same week as the forum announcement, showed a net loss of $12.4 million for the nine‑month period ended June 30 2023. The loss was driven by increased clinical‑development expenses and a $5.2 million equity financing that the company used to fund its Phase 2 lupus study and ongoing operations.

“While our burn rate remains consistent with a clinical‑stage biotech of Sig yn’s size, the capital raised gives us a 14‑month runway through the end of 2024, assuming no additional financing,” said Chief Financial Officer Alexandra Lee.

The equity round was led by a consortium of venture capital funds, including Berkshire Capital and Sapphire Venture Partners, with Global Health Ventures as the anchor investor. The funds will be deployed primarily toward the expansion of the SLE pipeline, support of the melanoma program, and scaling of the company’s manufacturing capabilities.

Key Data Highlights

SGT‑120 – Advanced Melanoma

• Safety: No grade ≥ 3 adverse events were reported in the 20‑patient cohort. The most common side effect was transient fatigue (grade 1–2) in 15 % of patients.
• Pharmacokinetics: Steady‑state trough concentrations were achieved by Day 7, and the drug displayed a half‑life of 12 hours, supporting once‑daily dosing.
• Immunologic Biomarkers: A 30 % increase in CD8+ T‑cell proliferation was observed in tumor biopsies, supporting the drug’s mechanism of action.

SGT‑201 – Metastatic NSCLC

• First‑in‑human dosing began in June 2023, with an open‑label safety cohort of 12 patients. Early data suggest a tolerable safety profile and signs of tumor shrinkage in two patients.

SGT‑301 – Systemic Lupus Erythematosus

• The company is preparing to launch a Phase 2b study in Q3 2024, with a target enrollment of 120 patients across 15 sites in North America and Europe. The study will evaluate the drug’s efficacy in reducing the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score.

Strategic Partnerships

Sig yn has entered a research collaboration with The University of Toronto’s Institute for Molecular Medicine to co‑develop a bispecific antibody that pairs SGT‑120 with a PD‑1 blocker. The partnership aims to generate pre‑clinical data by Q4 2024, paving the way for a Phase 1 combination study in 2025.

Additionally, the company is in talks with Johnson & Johnson to explore a co‑development arrangement for SGT‑301, given J&J’s strong foothold in the lupus therapeutic space.

Investor Forum Agenda

The September 18 virtual forum will cover:

1. Welcome & Company Overview – CEO Dr. Michael Chen introduces Sig yn’s mission and recent milestones.
2. Pipeline Update – Detailed presentation of SGT‑120 data and a brief look at Phase 1b and Phase 2 programs.
3. Financial Review – CFO Lee discusses quarterly results, burn rate, and capital needs.
4. Q&A Session – Live question and answer with the senior leadership team.
5. Closing Remarks – Next steps and upcoming milestones.

Investors can register for the event on the Sig yn Investor Relations website via the “Events” tab. The webcast will be available on Zoom and a replay will be posted on the company’s website after the live session.

Forward‑Looking Statements and Risks

Like all biotech press releases, the forum announcement contains forward‑looking statements. These statements are based on current expectations and involve risks, including but not limited to:

• Uncertainties surrounding the clinical‑development path of the company’s candidates.
• The potential for regulatory delays or changes in approval requirements.
• The need to secure additional financing to sustain operations beyond the current runway.
• Possible competitive responses from other checkpoint inhibitor developers.

Investors are advised to carefully review the company’s risk factors disclosed in its quarterly filings and the accompanying proxy statement.

Bottom Line

Sig yn Therapeutics is positioned at a pivotal juncture, with promising early‑stage data for its lead melanoma candidate and a robust pipeline that extends into lung cancer and autoimmune disease. The upcoming virtual investor forum on September 18 will provide a crucial platform for stakeholders to assess the company’s progress, understand its financial health, and gauge its strategic trajectory. With a solid partnership portfolio, a disciplined burn rate, and a clear path toward commercialization, Sig yn invites investors to join the conversation and stay informed about the next steps in its journey to deliver innovative therapies for patients in need.